AmorChem Ventures: The Translational Venture Fund

Transcription

1 AmorChem Ventures: The Translational Venture Fund

2 AmorChem Who we are What we do What we have Assets to highlight MiHA OXO ETE Semaphorin 3a Mucoadhesive nanoparticles

3 AmorChem Ventures is the first and only venture fund dedicated to translating early academic science into commercial innovation Seed financing and incubation of university technologies are at the core of the AmorChem model Sourced from Québec based universities and research centres INTELLECTUAL PROPERTY NUCHEM Wholly owned subsidiary Med chem CRO Company structure to hold licenses Fiscal structure for research tax credits AMORCHEM HOLDING AMORCHEM VENTURE Venture capital activity for commercialisation and business development 3

4 AmorChem activities that have contributed to its early success in accelerating innovation SOURCING AMORCHEM VENTURES DILIGENCE AMORCHEM HOLDING CRAFTING OF BUSINESS OPPORTUNITY AND PLAN IP MANAGEMENT NEGOTIATIONS: UNIVERSITY, TECH TRANSFER, RESEARCHERS NEGOTiATIONS WITH EXTERNAL PARTNERS PROJECT MANAGEMENT IMPLEMENT PHARMA STANDARDS IN PROJECTS NEGOTIATION OF MATURATION PLAN AND BUDGET BUDGET MANAGEMENT ACCOMPANIEMENT OF RESEARCHER NUCHEM THERAPEUTICS WET MEDICINAL CHEMISTRY IP CREATION CHEMISTRY DILIGENCE & CONSULTANCY PROJECT MANAGEMENT IMPLEMENT PHARMA STANDARDS IN PROJECTS 4

5 The principals behind the AmorChem model TRANSACTIONS FINANCINGS LEVERS EXITS LICENCES WITH UNIVERSITY BASED ON REVENUE SHARING FEASABILITY FIRST $500K TO $1M LAB INFRASTRUCTURE FROM PRINCIPAL INVESTIGATOR LICENCE RESEARCH AGREEMENT WITH PRINCIPAL INVESTIGATOR FOLLOW ON $1.M TO 3M$ NON DILUTIVE GRANTS START UP 5

6 : Building a portfolio from Québec based opportunities 400 PROPOSALS REVIEWED 25 LICENSE AGREEMENTS 27 RESEARCH CONTRACTS 24 PROJECTSFINANCED 31 PATENTS 90 FTE S 6

7 Portfolio of technologies diversified across multiple disease indications PCSK9 sm PCSK9 sdab CD36 CV UROTENSIN IGF TRAP 17BHSD 1 DNMTI AML AML GVHD MIHA CD73 CARDIOLOGY ONCOLOGY HEMATOLOGY DIAGNOSTICS IMMUNO ONCOLOY ABHD6 OXO ETE S100A9 DUB DM1 CFTR FRATAXIN CD36 AMD SEMA3A MNP POROUS SCREW GREATER TROCANTER METABOLIC INFLAMMATION ORPHAN OCULAR ORTHOPEDIC DEVICES In red are projects for which we have or will have intellectual property protection in China 7

8 Portfolio is well diversified across disease indication DEVICES, 8.30% CARDIO, 16.70% OCCULAR, 12.50% ONCOLOGY, 8.30% ORPHAN, 16.70% HEMATOLOGY, 4.00% DIAGNOSTICS, 8.30% INFLAMMATION, 12.50% IMMUNO ONCO, 8.30% METABOLIC, 4.00% 8

9 Portfolio well diversified across stage of development TARGET ID & VALIDATION HIT TO LEAD DUB CD36 AMD CD36 CV UROTENSIN S100A9 PCSK9 SM PCKS9 SDAB ABHD6 FRATAXIN CD73 LEAD OP DM1 SEMA3A CFTR PRE CLINICAL CLINICAL POROUS SCREW DNMTI OXO ETE IGF 1 TRAP GAG 17BHSD1 GREATER TROCANTER MNP MIHA GVHD DX AML DX 9

10 MiHA Immunotherapy for Hematological Cancers (HC) Technology T Cell therapy, Minor histocompatability antigens (MiHA) In order to be therapeutically useful, a MiHA must not only be PRESENT on host HC cells, but also be ABSENT in donor cells (otherwise, donor T cells would not recognize the MiHA as non self) Objective increase efficacy of hematopoetic stem cell transplantation & decrease incidence of GvHD Stage Ph1 clinical trial Next Steps initiate 24 pts Ph 1 trial in q Assets only cgmp cell therapy manufacturing facility in Canada situated in Montreal Indication Leukemia (AML)

11 Planned Phase I II trial: In vitro expansion of MiHA specific T cells Donor/recipient exome sequencing Selection of target MiHAs in vitro expansion (35 days) Injection of MiHA primed T cells MiHA In vitro expansion of MiHA primed T cells

12 5 oxo ete Most potent chemoattractant of eosinophils Technology small molecule single digit, pm, oral bioavailable, good PK profile, scale up & chiral synthesis Objective antagonize eosinophilia Stage Candidate for development Next Steps primate experiments dermal oxo ete & house dust mite (completed) Inhalation house dust mite induced asthma model (on going) Potential Indications Severe asthma, eosinophilic esophagitis, IBD, atopic dermatitis, VKC, nasal polyps Orphan hyper eosinophilic diseases

13 ALX-R Anti inflammatory Resolution of inflammation 5 Lipoxygenase pathway 15-LO LXA 4 Resolvins 15-LO/FLAP CO 2 H AA 5-LO inhibitor or FLAP antagonist (e.g. Zileuton) OOH 5-HpETE CO 2 H OH CO 2 H 5-HETE cyslt 2 -R LTC 4 synthase LTC 4 LTA 4 LTA 4 hydrolase 5-HEDH / NADP + LTD 4 LTB 4 cyslt 1 -R Asthma & allergy CysLT 1 antagonist (e.g. Montelukast) BLT 1 -R Inflammation (Host defense) OXE-R Inflammation (eosinophilia) Asthma?? Allergic Rhinitis?? Cancer?? OXE antagonist 13

14 5 Hydroxyeicosanoid dehydrogenase (5 HEDH) Relative rates of metabolism (% 5S-HETE) S-HETE 5R-HETE 8RS-HETE 9RS-HETE S OH 5S-HETE O 5-oxo-ETE 11RS-HETE CO 2 H 5-HEDH (Microsomes) NADP + CO 2 H 12S-HETE 15S-HETE LTB 4 Transcellular biosynthesis of 5-oxo-ETE AA Leukocyte 5-LO 5-HETE 5-HETE FLAP 5-HEDH 5-HEDH 5oxo-ETE Epithelial cell Expression of 5-HEDH activity Many types of leukocytes (neutrophils, eosinophils, monocytes, B cells) Platelets Epithelial cells Keratinocytes Endothelial cells Airway smooth muscle cells Tumor cells 14

15 Semaphorin 3A TRAPS Technology biologic, engineered protein targeting semaphorin 3A &VEGF Objective demonstrate efficacy in diabetes related ocular diseases & vascular leakage Stage lead optimization Next Steps select candidate for development, cgmp manufacturing to enable in vivo & IND enabling studies Potential indications Ocular (DME, DR, AMD) Others Acute kidney injury, diabetic nephropathy, stroke, concussion, sepsis, oncology (prostate), immuno oncology

16 DIABETIC RETINOPATHY Semaphorin 3A STZ treated diabetic mice have increased retinal expression of Sema3A Mice (n=13) were injected intraperitoneally with 55mg STZ/kg body weight for 5 consecutive days. 16

17 Mucoadhesive Nanoparticles Technology platform drug delivery, delivers drug from hrs. to 5 days, covalently binds to mucous membranes Objective advance technology to IND enabling studies Stage dry eye PoC has been achieved Next Steps cgmp manufacturing, expand the potential of the technology, feasibility testing of various molecules for partners Indications Ocular dry eye, glaucoma, conjunctivitis, uveitis, etc. Other membranes respiratory, nasal, oral, genital, etc.

18 Technology Description Long lasting topical drops using mucoadhesive nanoparticles (MNPs) MNPs carry a large dose of ocular drug of choice MNPs establish strong covalent adhesion towards ocular mucous membrane MNPs release drugs at a sustained and tunable rate MNPs do not cause irritation due to nano scale sizes 18

19 Treatment of Experimental Dry Eye in Mice After one week of Dry Eye Syndrome treatment: Saline (1/wk.) MNP w. CycA (1.5 µg x 1/wk.) Restasis (1.5 µg x 3/day) Inflammation (red arrows) Inflammation is eliminated Goblet cells are also restored Inflammation is eliminated No goblet cells Once weekly administration of cyclosporine A encapsulated MNPs eliminated inflammation and restored goblet cells in the treatment of dry eye. 19

20 Thank you for your attention I look forward to meeting & discussing potential relationships with you